Hostname: page-component-8448b6f56d-sxzjt Total loading time: 0 Render date: 2024-04-24T06:18:37.939Z Has data issue: false hasContentIssue false
  • English
  • Français

The health economic implications of treatment with quetiapine: an audit of long-term treatment for patients with chronic schizophrenia

Published online by Cambridge University Press:  16 April 2020

J. Lynch ,
J. Morrison ,
N. Graves ,
D. Meddis ,
M.F. Drummond  and
J.S.E. Hellewell
J. Lynch
Affiliation:
St Lukes Hospital, Clonmel, Republic of Ireland
J. Morrison
Affiliation:
St Lukes Hospital, Clonmel, Republic of Ireland
N. Graves
Affiliation:
Department of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK
D. Meddis*
Affiliation:
AstraZeneca, Mereside, Alderley Park, Macclesfield, CheshireSK10 4TG, UK
M.F. Drummond
Affiliation:
Centre for Health Economics, University of York, York, UK
J.S.E. Hellewell
Affiliation:
Trafford General Hospital, Manchester, UK
*
*Correspondence and reprints.
Get access

Summary

This retrospective, case series audit assessed the clinical and health-economic impact of long-term treatment with quetiapine (‘Seroquel’), a new atypical antipsychotic, in patients with chronic schizophrenia.

The study design was of a case series format, comprising patients entered from one centre into the open-label extension of a multicentre 6-week efficacy study. Twenty-one patients (15 male, six female; mean age 39 years) were studied, of whom 17 (81%) had been rated as ‘partially responsive’ to previous antipsychotics. Data on hospitalisations and information on symptoms were collected retrospectively for the 12 months before quetiapine treatment was initiated and for the 12 months after.

Quetiapine was effective in reducing psychotic symptoms with mean BPRS scores reducing significantly, from 38 to 21 (P < 0.005). Motor function was also significantly improved with mean Simpson scale scores reducing from 15 to 12 (P < 0.005). Average inpatient days were reduced by 11% in year two (97 compared with 109 days) while the overall costs of treatment, including drug costs, fell by 5% (I£20,843 to I£19,827).

Four patients had been hospitalised for longer than 5 years before starting quetiapine; these chronically institutionalised patients remained in hospital, despite improved clinical outcomes (mean BPRS scores after treatment of 34, compared with 43 before), for the full 12 months of quetiapine treatment. Were the data from this audit to be re-analysed excluding these four patients then average inpatient days would have been reduced by 33% (45 to 30 days) and overall cost of treatment by 19% (I£8617 to I£7011).

This audit suggests that treatment with quetiapine over this 1-year period was associated with both clinical improvements and a decreased usage of inpatient services. The reduction in hospitalisation costs would appear to compensate for the increased cost of drug treatment. Significantly, potential savings appear to be greatest for those patients with a ‘revolving door’ pattern of repeated readmission.

Keywords

antipsychoticaudithealth economicsquetiapineschizophrenia
Type
Original article
Information
European Psychiatry , Volume 16 , Issue 5 , August 2001 , pp. 307 - 312
Copyright
Copyright © Éditions scientifiques et médicales Elsevier SAS 2001

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Addington, DEJones, BBloom, DChouinard, GRemington, GAlbright, P.Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clin Ther 1993; 15: 917–26.Google ScholarPubMed
Aitchison, KJKerwin, RW.Cost-effectiveness of clozapine. Br J Psychiatry 1997; 171: 125–30.CrossRefGoogle ScholarPubMed
Almond, SO'Donnell, OO.(1998) Cost analysis of the treatment of schizophrenia in the UK. A comparison of olanzapine and haloperidol. Pharmacoeconomics 1998; 13: 575–88.CrossRefGoogle Scholar
Arvanitis, LAMiller, BG. the Seroquel Trial 13 Study Group Multiple fixed doses of ‘Seroquel’ (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997; 42: 233–46.CrossRefGoogle Scholar
Buchanan, A.A two-year prospective study of treatment compliance in patients with schizophrenia. Psychol M 1992; 22: 787–97.CrossRefGoogle ScholarPubMed
Davies, LMDrummond, MF.Economics and schizophrenia: the real cost. Br J Psychiatry 165Suppl251994 18–21.CrossRefGoogle Scholar
Drummond, MFKnapp, MRJBurns, TPMiller, KDShadwell, P.Issues in the design of studies of the economic evaluation of new atypical antipsychotics: the ESTO study. J Ment Health Policy Econ 1998; 1: 15–22.3.0.CO;2-O>CrossRefGoogle ScholarPubMed
Edgell, ETAndersen, SWJohnstone, BMDulisse, BRevicki, D.Olanzapine versus risperidone: a prospective comparison of clinical and economic outcomes in schizophrenia. Pharmacoeconomics 2000; 18: 567–79.CrossRefGoogle Scholar
Evers, SMAAAment, AJHA.Costs of schizophrenia in the Netherlands. Schizophr Bull 1995; 21: 141–53.CrossRefGoogle ScholarPubMed
Finley, PRSommer, BRCorbitt, JLBrunson, GHLum, BL.Risperidone: clinical outcome predictors and cost-effectiveness in a naturalistic setting. Psychopharmacol Bull 1998; 34: 75–81.Google Scholar
Glazer, WMJohnstone, BM.Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia. J Clin Psychiatry 58Suppl101997 50–4.Google Scholar
Guest, JFHart, WMCookson, RFLindström, E.Pharmacoeconomic evaluation of long-term treatment with risperidone for patients with chronic schizophrenia. Br J Med Econ 1996; 10: 59–67.Google Scholar
Guy, W, ECDEU Assessment manual for psychopharmacology. Publication ADM 76–338. Rockville (MD): National Institute of Mental Health; 1976.Google Scholar
Guy, W., Abnormal involuntary movements. In: Guy, W, Ed. ECDEU Assessment manual for psychopharmacology. Publication ADM 76–338. Rockville (MD): National Institute of Mental Health. p.217–22.Google Scholar
Hart, WMLindstrom, EGuest, JF.Economic impact of the use of risperidone for the treatment of chronic schizophrenia in Ireland. Ir J Psychiatry Spring/Summer1997 12–6.Google Scholar
Hamner, MBArvanitis, LAMiller, BG.Plasma prolactin in schizophrenia patients treated with Seroquel (ICI 204,636). Psychopharmacol Bull 1996; 32: 107–10.Google Scholar
Hellewell, JSEKalali, AHLangham, SJMcKellar, JAwad, AG.Patient satisfaction and acceptability of long-term treatment with quetiapine. Int J Psychiatry Clin Practice 1999; 3: 105–13.CrossRefGoogle ScholarPubMed
Hong, WWRak, IWCiuryla, VTWilson, AMKylstra, JWMeltzer, HY., et al. Medical-claims databases in the design of a health-outcomes comparison of quetiapine (‘Seroquel') and usual-care antipsychotic medication. Schizophr Res 1998; 3: 51–8.CrossRefGoogle Scholar
Kasper, SMüller-Spahn, F.Review of quetiapine and its clinical applications in schizophrenia. Expert Opin Pharmacother 2000; 4: 783–801.CrossRefGoogle Scholar
Keks, NA.Impact of newer antipsychotics on outcomes in schizophrenia. Clin Ther 1997; 19: 148–58.CrossRefGoogle Scholar
Kerwin, RTaylor, D.New antipsychotics: a review of their current status and clinical potential. CNS Drugs 1996; 6: 71–82.CrossRefGoogle Scholar
King, DJLink, CGGKowalcyk, B.A comparison of bd and tid dose regimens of quetiapine (‘Seroquel') in the treatment of schizophrenia. Psychopharmacology 1998; 137: 139–46.CrossRefGoogle Scholar
Knapp, M.Costs of schizophrenia. Br J Psychiatry 1997; 171: 509–18.CrossRefGoogle ScholarPubMed
Meltzer, HY.Pre-clinical pharmacology of atypical antipsychotic drugs: a selective review. Br J Psychiatry 168Suppl291996 23–31.CrossRefGoogle Scholar
Meltzer, HYCola, PWay, LThompson, PABastani, BDavies, MA, et al. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry; 150: 1630–8.Google Scholar
Monthly index of medical specialties. 1999.Google Scholar
Overall, JEGorham, DE.The brief psychiatric rating scale. Psychiatr Rep 1962; 10: 799–812.Google Scholar
Peuskens, JLink, CGG.A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997; 96: 265–73.CrossRefGoogle ScholarPubMed
Revicki, DALuce, BRWeschler, JMBrown, REAdler, MA.Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients. Hosp Community Psychiatry 1990; 41: 850–4.Google ScholarPubMed
Rozenheck, RCramer, LXu, WThomas, JHenderson, W.Frisman L, for the Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. New Engl J M 1997; 337: 809–15.CrossRefGoogle Scholar
Rupp, AKeith, SJ.The costs of schizophrenia. Psychiatr Clin N Am 1993; 16: 413–23.CrossRefGoogle ScholarPubMed
Roullion, FToumi, MDansett, GY., et al. Some aspects of the cost of schizophrenia in France. Pharmacoeconomics 1997; 1: 578–94.CrossRefGoogle Scholar
Simpson, GMAngus, JWS.A rating scale for extrapyramidal side effects. Acta Scand Psychiatr 212Suppl1970 11–9.CrossRefGoogle ScholarPubMed
Small, JGHirsch, SRArvantitis, LAMiller, BGLink, CGG, and the Seroquel Study Group. Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 1997; 54: 549–57.CrossRefGoogle ScholarPubMed
Van Putten, T.Why do schizophrenic patients refuse to take their drugs. Arch Gen Psychiatry 1974; 31: 67–72.CrossRefGoogle ScholarPubMed
Viale, GMechling, LMaislin, GDurkin, MEngelhart, LLawrence, BJ.Impact of risperidone on the use of mental health care resources. Psychiatr Services 1997; 48: 1153–9.Google ScholarPubMed
Wyatt, RJHenter, I.Leary MC, et al (1995) An economic evaluation of schizophrenia – 1991. Soc Psychiatry Psychiatr Epidemiol 1995; 30: 196–205.Google ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.